solid
organ
hematopoiet
stem
cell
transplant
recipi
well
receiv
chemotherapi
malign
hematolog
diseas
clearli
predispos
subject
varieti
viral
infect
common
opportunist
diseas
patient
may
acquir
infect
commun
well
donor
organ
donorderiv
infect
andor
reactiv
endogen
latent
viru
herp
virus
especi
cytomegaloviru
epsteinbarr
viru
among
common
opportunist
viral
pathogen
affect
patient
addit
respiratori
virus
treatment
consist
antivir
drug
therapi
combin
reduct
degre
induc
immunosuppress
review
literatur
perform
order
updat
epidemiolog
pathogenesi
clinic
manifest
therapeut
approach
viral
infect
immunocompromis
patient
resumen
ser
receptor
de
un
trasplant
de
como
recibir
tratamiento
para
una
enfermedad
maligna
predispon
clarament
padec
infeccion
viral
tanto
comun
como
oportunista
de
origen
tanto
comunitario
como
procedent
del
donant
de
yo
de
una
de
un
viru
latent
herp
viru
especialment
citomegaloviru
viru
de
epsteinbarr
son
lo
que
con
frecuencia
afectan
esto
enfermo
como
lo
viru
respiratorio
el
tratamiento
consist
en
la
de
reducir
la
inducida
junto
con
tratamiento
antivir
se
ha
realizado
una
de
la
literatura
pormenorizada
actualizada
de
la
la
patogenia
la
manifestacion
la
de
la
infeccion
viral
en
esto
enfermo
last
two
decad
solid
organ
transplant
sot
becom
treatment
choic
mani
diseas
past
led
patient
death
due
failur
one
vital
organ
addit
develop
differ
surgic
anesthet
techniqu
doubt
advanc
immunosuppressor
treatment
play
key
role
allow
improv
therapi
infect
frequent
complic
transplant
recipi
main
caus
death
first
year
transplant
sot
recipi
particularli
vulner
common
opportunist
viral
infect
infect
may
deriv
donor
organ
donorderiv
infect
may
communityacquir
correspond
reactiv
latent
endogen
virus
patient
apart
direct
harm
effect
mani
virus
mention
must
made
immun
modul
inflammatori
action
give
rise
import
indirect
effect
acut
chronic
graft
reject
favor
opportunist
infect
extens
herpesviru
famili
particularli
cytomegaloviru
cmv
epsteinbarr
viru
ebv
among
frequent
opportunist
viral
pathogen
caus
infect
sot
patient
virus
close
follow
order
frequenc
import
herp
simplex
viru
hsv
varicellazost
viru
vzv
type
human
herp
viru
infecti
syndrom
typic
produc
last
two
decad
two
new
type
herpesviru
ad
hand
certain
type
sot
liver
transplant
hepatotrop
virus
hepat
b
viru
hbv
hepat
c
viru
hcv
also
import
condit
transplant
outcom
refer
communityacquir
virus
practic
caus
infect
sot
patient
though
recent
time
special
emphasi
place
respiratori
virus
respiratori
syncyti
viru
rsv
influenza
parainfluenza
virus
metapneumoviru
mpv
bocaviru
neurotroph
virus
lymphocyt
choriomening
viru
lcmv
west
nile
viru
wnv
rabi
viru
well
virus
caus
measl
mump
coronaviru
rotaviru
viral
infect
sot
patient
condit
least
three
group
factor
modifi
frequenc
time
form
present
transplant
organ
surgic
modal
techniqu
use
transplant
immun
suppress
protocol
use
relationship
serolog
statu
donor
recipi
dr
statu
prophylact
measur
adopt
prevent
develop
viral
diseas
univers
prophylaxi
select
riskadapt
prophylaxi
prolong
prophylaxi
defer
prophylaxi
anticipatori
therapi
infect
risk
period
viral
infect
way
infect
caus
microorgan
follow
defin
chronolog
pattern
involv
well
defin
period
fig
first
period
cover
first
four
week
surgeri
interv
risk
infect
high
fundament
relat
nosocomi
bacteria
lesser
degre
fungi
candida
aspergillu
clinic
manifest
similar
found
surgic
patient
viral
infect
infrequ
phase
second
period
extend
end
postop
interv
sixth
month
risk
infect
case
lower
microorgan
involv
tend
opportunist
organ
includ
mani
aforement
virus
third
period
start
sixth
month
transplant
risk
infect
decreas
consider
infect
usual
produc
outhospit
microorgan
period
minor
patient
graft
organ
evolv
correctli
may
suffer
infect
characterist
preced
two
period
common
opportunist
virus
abl
produc
broad
rang
infecti
syndrom
differ
clinic
behavior
sot
recipi
disord
may
rang
scantli
express
oligosymptomat
clinic
condit
character
fever
detect
viremia
process
extrem
seriou
seriou
structur
function
damag
graft
organ
suscept
infect
greater
damag
target
organ
due
special
tropism
shown
virus
dissemin
system
natur
context
mention
made
f
p
l
e
n
f
e
c
n
u
e
c
v
w
h
f
e
v
e
r
n
cytomegaloviremia
also
seriou
organspecif
diseas
enterocol
hemorrhag
characterist
case
pneumonia
includ
even
bilater
alveolointerstiti
pattern
sever
respiratori
failur
adult
respiratori
distress
syndrom
ard
hepat
retin
enceph
similar
behavior
shown
virus
herp
famili
hsv
vzv
caus
less
extens
characterist
vesicular
nonvesicular
exanthemat
mucocutan
diseas
particular
abl
spread
affect
organ
present
particularli
seriou
natur
includ
hepat
pneumon
gastrointestin
form
esophag
coliti
especi
neuroophthalmolog
form
meningoenceph
encephalomyel
retin
fortun
viral
famili
suscept
treatment
specif
antivir
agent
establish
efficaci
context
ebv
caus
variou
type
distinct
infecti
syndrom
tabl
though
posttransplant
lymphoprolif
diseas
ptld
particular
import
due
clinic
repercuss
exclus
manag
characterist
polyomavirus
produc
broad
rang
relev
clinic
condit
depend
upon
tropism
invas
give
rise
sever
demyelin
p
h
e
n
e
n
u
c
h
p
r
g
r
e
v
e
u
l
f
c
l
leukoencephalopathi
pml
case
jcv
vari
number
process
case
bkv
graft
interstiti
nephropathi
renal
transplant
risk
transplant
organ
loss
ureter
stenosi
hemorrhag
cystiti
meningoenceph
urotheli
carcinoma
tabl
erythroviru
show
strong
attract
hematopoiet
precursor
particularli
red
cell
line
caus
seriou
refractori
aplast
anemia
pancytopenia
well
induc
arthriti
rash
risk
seriou
organ
diseas
de
novo
hepat
reactiv
reinfect
recurr
diseas
due
hbv
hcv
caus
seriou
inconveni
sot
patient
affect
prognosi
outcom
transplant
particularli
case
liver
transplant
patient
contrast
hbv
recurr
effect
contain
specif
immunoglobulin
antivir
agent
effect
prophylaxi
hepat
c
avail
diseas
almost
sure
prove
recurr
posttranspl
evolut
depend
prevent
reinfect
transplant
organ
limit
differ
host
factor
toxic
antivir
drug
use
hcvinclud
pegyl
interferon
substanti
proport
hcv
infect
patient
suffer
termin
recurr
liver
allograft
diseas
lead
diminish
surviv
r
n
p
l
n
e
r
g
n
n
n
c
r
e
e
n
e
e
f
r
l
v
e
r
retransplant
ultim
reduct
patient
surviv
aspect
gain
increas
import
follow
introduct
earli
decad
liver
transplant
procedur
patient
coinfect
human
immunodefici
viru
hiv
hcv
sinc
individu
exhibit
faster
cirrhosi
progress
rate
lead
increas
frequenc
cirrhosi
termin
liver
diseas
hepatocellular
carcinoma
treatment
viral
infect
sot
patient
effect
antivir
drug
must
complement
reduct
grade
intens
immun
suppress
hematolog
patient
present
differ
type
immun
disord
depend
hematolog
diseas
involv
evolut
statu
treatment
provid
immun
problem
favor
develop
seriou
case
treatment
failur
ganciclovir
foscarnet
caus
seriou
advers
effect
well
toler
fail
elicit
suffici
respons
administr
serum
creatinin
urin
protein
determin
administ
cidofovir
probenecid
via
oral
rout
intraven
salin
solut
prehydr
measur
c
joint
use
ganciclovir
immunoglobulin
shown
effect
hematopoiet
precursor
cell
transplant
sot
group
extrapol
result
patient
though
definit
evid
respect
infect
turn
increas
patient
morbiditymort
recent
year
viral
infect
gain
import
group
patient
clinic
practic
classifi
oncohematolog
patient
hematopoiet
precursor
cell
transplant
hpct
recipi
blood
product
recipi
epidemiolog
chang
spectrum
sever
viral
infect
increas
among
patient
year
ago
usual
suffer
infect
larg
consequ
use
new
drug
mark
immunosuppressor
effect
three
type
immun
defici
neutropenia
cellular
immun
defici
humor
immun
defici
type
immun
depress
associ
certain
type
infect
howev
differ
type
immun
defici
tend
coexist
case
hematolog
diseas
pcr
result
interpret
caution
possibl
latent
infect
exist
c
therapi
might
use
though
efficaci
suffici
establish
neutropenia
predomin
patient
acut
leukemia
marrow
aplasia
evolv
myelodysplast
syndrom
patient
subject
intens
chemotherapi
situat
infect
predominantli
caus
gramposit
gramneg
bacteria
fungi
virus
herp
rsv
influenza
parainfluenza
cellular
immun
defici
turn
appear
patient
w
h
h
g
k
n
l
p
h
n
h
e
r
v
n
c
e
lymphoprolif
syndrom
treatment
glucocorticoid
purin
analog
treatment
monoclon
antibodi
situat
common
find
infect
caus
intracellular
bacteria
virus
cmv
hsv
vzv
jcv
rsv
fungi
parasit
lastli
humor
immun
defici
predomin
p
e
n
w
h
u
l
p
l
e
e
l
wa
l
e
n
r
macroglobulinemia
chronic
lymphat
leukemia
cll
splenectom
subject
infect
less
frequent
previou
group
fundament
caus
encapsul
bacteria
hpct
treatment
option
hematolog
diseas
mainli
malign
blood
disord
infect
import
complic
due
summ
immun
depress
caus
background
neoplast
diseas
condit
regimen
administ
transplant
treatment
reject
graftversushost
diseas
gvhd
infect
risk
factor
consider
whether
donor
rel
patient
viral
serolog
condit
prior
transplant
time
develop
infect
transplant
three
predict
immun
defici
risk
period
hpct
immedi
posttranspl
period
start
condit
treatment
persist
day
transplant
period
character
intens
neutropenia
lymphocytopenia
regard
viral
infect
phase
common
condit
reactiv
hsv
previous
seroposit
patient
earli
postgraft
period
start
neutrophil
recoveri
persist
day
function
recoveri
b
cell
occur
howev
presenc
gvhd
treatment
may
delay
immun
recoveri
cmv
import
infecti
agent
phase
viral
infect
note
phase
produc
rsv
influenza
parainfluenza
viru
rhinovirus
gastroenter
due
rotaviru
coxsacki
viru
reactiv
adenovirus
late
postgraft
period
extend
day
recoveri
normal
immun
month
hpct
provid
patient
subject
immun
suppress
remain
free
gvhd
period
may
reactiv
vzv
infect
due
cmv
particularli
seroposit
patient
chronic
gvhd
herp
simplex
viru
frequent
clinic
manifest
gingivostomat
though
case
diseas
spread
esophagu
larynx
skin
perior
perian
region
sometim
difficult
distinguish
mucos
caus
hsv
caus
chemotherapi
result
empir
antivir
therapi
usual
indic
reactiv
hsv
reduc
less
seroposit
recipi
first
month
transplant
prescrib
aciclovir
valaciclovir
time
condit
recoveri
mucos
see
treatment
prophylaxi
tabl
varicella
zoster
viru
manifest
primari
infect
reactiv
patient
time
first
year
transplant
patient
import
cellular
immun
defici
hodgkin
lymphoma
patient
condit
previous
common
cll
receiv
treatment
new
immunosuppressor
drug
fludarabin
rituximab
alemtuzumab
addit
typic
cutan
form
present
hemorrhag
pneumonia
hepat
central
nervou
system
involv
thrombocytopenia
retin
necrosi
may
observ
occasion
patient
hpct
viscer
involv
occur
without
preced
skin
lesion
gvhd
potent
predictor
dissemin
mortal
increas
presenc
lung
involv
treatment
summar
tabl
cytomegaloviru
cmv
infect
import
complic
patient
subject
hpct
although
incid
cmv
diseas
decreas
recent
year
thank
prevent
strategi
adopt
cmv
seroposit
consid
independ
risk
factor
gvhd
associ
poorer
surviv
increas
mortal
due
bacteremia
fungal
infect
transplantrel
mortal
manifest
cmv
infect
target
organ
pneumonia
enterocol
rare
retin
cmv
pneumonia
frequent
seriou
manifest
even
treatment
mortal
rate
disord
infrequ
prior
graft
consolid
howev
hand
cmv
pneumonia
seen
behav
emerg
infect
adult
leukemia
patient
treat
immunosuppressor
drug
hpct
recipi
classifi
differ
cmv
diseas
risk
group
high
risk
assum
allogen
transplant
cell
deplet
precursor
cell
sourc
donor
rel
absenc
ident
histocompat
antigen
hla
use
highdos
corticosteroid
treatment
alemtuzumab
purin
analog
autolog
transplant
select
treat
purin
analog
highdos
corticosteroid
tabl
diagnost
techniqu
choic
earli
detect
infect
antigenemia
pcr
relat
diagnosi
import
appli
consensusbas
criteria
infect
diseas
regimen
relat
prophylaxi
anticipatori
treatment
guid
treatment
explain
tabl
communityacquir
respiratori
tract
virus
frequent
patient
subject
hpct
leukemia
patient
subject
chemotherapi
paramyxovirus
rsv
pa
ra
n
flu
e
n
za
vi
ru
e
p
n
e
u
v
r
u
orthomyxovirus
influenza
b
rhinoviru
coronaviru
adenovirus
bocaviru
among
other
respiratori
viral
infect
tend
manifest
relat
season
outbreak
acquir
contact
infect
individu
pneumonia
develop
associ
mortal
rate
high
particularli
case
rsv
parainfluenza
viru
treatment
establish
efficaci
infect
though
inhalatori
ribavirin
recommend
case
rsv
pneumonia
neuraminidas
inhibitor
oseltamivir
zanamivir
advis
case
influenza
viru
effect
chemoprophylact
measur
avail
infect
oncohematolog
patient
therefor
essenti
prevent
patient
becom
expos
viru
includ
nosocomi
transmiss
adenovirus
infect
consequ
viral
reactiv
occur
approxim
allogen
hpct
recipi
smaller
proport
autolog
hpct
recipi
frequent
manifest
hemorrhag
cystiti
though
system
pulmonari
hepat
gastrointestin
renal
infect
also
develop
gvhd
adenoviru
infect
risk
factor
follow
hpct
effect
treatment
infect
virus
erythroviru
patient
chronic
hemolyt
anemia
produc
redcel
aplast
episod
hpct
patient
infrequ
caus
anemia
polyomavirus
jc
viru
bk
viru
give
rise
progress
multifoc
leukoencephalopathi
pml
hemorrhag
cystiti
respect
case
ebv
reactiv
subclin
requir
treatment
though
case
pleomorph
lymphoma
ptl
high
mortal
may
result
hpct
give
rise
u
n
f
e
l
u
p
p
r
e
n
k
n
r
h
meningoenceph
gvhd
exacerb
turn
relat
bone
marrow
hypoplasia
kaposi
sarcoma
multicentr
castleman
diseas
caviti
b
cell
lymphoma
treatment
fludarabin
purin
analog
alemtuzumab
kappa
human
monoclon
tabl
prevent
treatment
viral
infect
hpct
hematolog
process
prevent
treatment
antibodi
associ
increas
frequenc
infect
due
hsv
vzv
infect
diseas
caus
cmv
rituximab
chimer
monoclon
antibodi
target
receptor
associ
develop
pure
redcel
aplasia
due
enteroviru
fulmin
hepat
due
hbv
reactiv
latent
hbv
infect
case
fatal
dissemin
varicella
infect
cmv
pneumonia
infect
due
hsv
vzv
periimpl
administr
autolog
hpct
associ
unusu
infect
pml
retin
cmv
pneumon
